Chemiesynth(Vapi (539230)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Trading at an 18% discount to book value: P/B 0.82 against book value ₹37.63
• Sales growth of 31.19% shows revenue traction despite weak profitability
• ROCE is positive at 3.10%, so operating assets are generating some return
• Latest quarter sales of ₹5 Cr indicate the business is still operational

Concerns

• Loss-making latest quarter: net profit -₹1 Cr on revenue of ₹5 Cr, with ROE at -12.19%
• Profit growth is deeply negative at -48.94%, and P/E is meaningless due to zero earnings
• Piotroski F-Score of 4/9 suggests weak financial health
• Stock is at its 52-week low of ₹30.98, down from ₹60.63, reflecting market skepticism

AI Analysis

Let me look at Chemiesynth(Vapi as Graham would: a small specialty chemicals company with a market cap of just ₹12 crore and a share price of ₹30.98, sitting below book value of ₹37.63. That P/B of 0.82 initially catches my eye. But a stock is not cheap simply because it trades below book; the book must earn a return. Here the numbers warn me. ROE is -12.19%, and the latest quarter lost ₹1 crore on sales of ₹5 crore. Profit growth has declined 48.94%. Book value is being eroded, not compounded. Sales growth of 31.19% is a positive, but growth without profits is often a trap. ROCE is only 3.10%, barely enough to attract me as a disciplined investor. The Piotroski F-Score of 4/9 reinforces weak financial health. There is no dividend, so the investor must rely on asset backing or future earnings. As a value investor, I prefer a durable moat. In specialty chemicals, a niche product with pricing power can be a good business, but I do not see evidence of a moat in these figures. At below book value, this is more of an asset play than a great business. I would demand a wide margin of safety because the quality is poor. Mr. Market has marked the stock down from ₹60.63 to its 52-week low, and with negative earnings I can understand the pessimism. If the company can turn sales into profits, there may be a turnaround. If not, the discount to book may be fair. I will not buy based on hope. I need evidence of improving margins, stable returns on capital, and eventually earnings that justify the book value.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer